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Burkitt’s lymphoma (BL) is an aggressive B-cell malignancy with very high proliferation rate, more common in males than females.
Here, we describe a case of Burkitt’s lymphoma in a 24-week pregnant woman with cervical and abdominal involvement. The
common genetic event of virtually all BL is a reciprocal chromosomal translocation involving the proto-oncogene MYC and one
of the Ig gene heavy or light chain loci. Supportive treatment was administered until early delivery, after which the patient was
treated according to protocol LMB96. Pregnancy and tumorogenesis share some important events such as immunologic tolerance,
angiogenesis, and editing the host immune response. Little is known about the relationship between these events in pregnancy and
in tumorogenesis.
1. Introduction
Burkitt’s lymphoma was first described in 1957 by the Irish
surgeon Dennis Parsons Burkitt, after observation of a so-
called “sarcoma of the jaws” in children in Uganda, Africa.
Burkitt’s lymphoma (BL) is a highly aggressive non-Hodgkin
lymphoma (NHL),with a very fast growth rate, often affecting
extranodal sites or with leukemic presentation [1]. Burkitt’s
lymphoma is usually diagnosed in children and young adults
and, to a lesser extent, in middle-aged adults [2]. Based on
epidemiology, three different forms of Burkitt’s lymphoma
have been described until now, an endemic form, a sporadic
form, and one related to HIV infection. The endemic form
(very common in Africa and Papua New Guinea) is strongly
associated (95%)with Epstein-Barr virus (EBV) infection and
malaria [3] and usually affects children that present with
facial bones involvement.
The sporadic form (5–15% associated with EBV) affects
mainly abdominal viscera, terminal ileum, caecum, mesen-
tery, andWaldeyer ring; the third variant is usually associated
with HIV infection, and 45% of patients are coinfected with
EBV. Burkitt’s lymphoma is more common in males than
females [4].
The common genetic event of virtually all BL is a recipro-
cal chromosomal translocation involving the proto-oncogene
MYC (on chromosome 8) and one of the Ig gene heavy or
light chain loci (on chromosomes 2, 14, or 22) [4]. The vast
majority of Burkitt’s lymphomas exhibit t(8; 14)(q24; q32).
As a result of the reciprocal chromosomal translocation, the
oncogene c-myc is overexpressed under the influence of Ig
enhancers regulatory regions. Constitutive expression of c-
myc oncogene promotes an increased B-cell proliferation, as
well as a reduced capacity for induction of apoptosis [5].
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Burkitt’s lymphoma/leukemia was one of the first malig-
nancies shown to be curable with intensive chemotherapy,
and the majority of children and young adult patients are
curable today with aggressive combination chemotherapy
regimens [2].
2. Case Presentation
A twenty-five years old woman, in the 24th week of gestation,
presented with a voluminous cervical mass located on the left
front neck. She had first noticed an enlargement of her neck 3
months earlier, and, apart from tiredness, she was completely
asymptomatic.
On observation, she had an isolated cervical mass of
about 5 × 10 cm long, hard on palpation, not mobile.
Fine needle aspiration showed a high grade B-cell lym-
phoma, CD10+ (flow cytometry), and the biopsy to the cer-
vical lesion confirmed the diagnosis of Burkitt’s lymphoma
with gene break point on MYC (8q24) determined by FISH
(fluorescent in situ hybridization). The tumour was CD20
(+), CD10 (+), Ki67 (+) (>90% of cells) (Figure 1), CD3 (−),
BCL2 (−), and TdT (−). The patient is HIV-1 negative, HIV-2
negative, EBV Ig G positive, and EBV Ig M negative.
As she was pregnant at the time of diagnosis, a total body
MRI (magnetic resonance imaging) was used for staging
instead of conventional CT scan. MRI revealed a cervical
mass of 104 × 63 × 75mm deviating the trachea and oesopha-
gus leftwards and in the infra diaphragmatic compartment,
a mass measuring 135 × 116 × 94mm in the right flank
and a fetus of approximately 25 weeks (Figure 2). There
were no bone marrow infiltration and no central nervous
system (CNS) infiltration, and the LDH level was elevated
(1376 𝜇L/L). According to the Murphy/St. Jude staging classi-
fication for Burkitt’s lymphoma, the patient was in stage III. In
an intention to safely carry on the pregnancy until week 28 of
gestation, under monitoring by an obstetrician, chemother-
apy with agents potentially less harmful for the baby
was proposed. Cyclophosphamide, doxorubicin, vincristine,
prednisone, plus rituximab (R-CHOP) was performed with
reduction of the cervical mass; however, in two weeks’ time,
the mass started growing again and LDH increased. Delivery
was performed at 28th week of gestation +5, and a healthy
babywas born by caesarean section. After delivery, the patient
proceeded with conventional treatment for BL according to
LMB-96 protocol, group B [6], without major complications.
Assessment of treatment response after R-CYM (cytara-
bine, methotrexate, and rituximab) by CT and PET scan
showed complete remission, and the patient completed
chemotherapy according to LMB96 group B protocol in
August 2012, with persisting complete remission.
3. Discussion
WhereasMYC translocation is found in almost all BL, it may
be seen as well in some cases of diffuse large B-cell lymphoma
(DLBCL) which is much more common, and may have a
different treatment approach [7].
Burkitt’s lymphoma’s brief and intense treatment regi-
mens have led to high cure rates even in adults, especially
Figure 1: Ki67 almost 100%.
Figure 2: MR coronal cut revealing a fetus and the abdominal tum-
our mass.
when immunotherapeutic approach is used [8]. Rituximab is
a monoclonal antibody specific to CD20 that induces death
on B cells by antibody-dependent cell-mediated cytotoxicity
[9]. Early diagnosis and intense and short treatment regimens
are ways of increasing cure rates [8].
This is an interesting case not only because it was not
possible to determine if it is purely extranodal BL (most
common), but also because the patient was pregnant.
A diagnosis of Burkitt’s lymphoma during pregnancy
implies difficulties both in staging procedures and in treat-
ment decision. Conventional stagingmethods as CT and PET
scan should not be performed, and BL treatment protocol
such as LMB-96 includes high-dosemethotrexate and cytara-
bine which are contraindicated during pregnancy. Using
alternative diagnostic means, chemotherapy regimens with
drugs potentially less harmful for the baby and a close follow-
up together with obstetric consult are crucial.
Immunologic tolerance, establishment of a nutrient sup-
ply system (angiogenesis), and evasion or editing the host
immune response are essential steps for a normal pregnancy
and also for tumorogenesis. Epithelial-mesenchymal transi-
tion, loss of integrin, and E-cadherin expression are essential
for the invasion processes in pregnancy and tumor growth.
Vasculogenic mimicry (nonendothelial cell assumes form
and function of a vascular structure) is a process observed
in extra villous trophoblast (EVT) cells (invasion of spiral
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arteries of maternal decidua, early in placental development)
and in some aggressive melanoma cells, sharing the same
event—expression of galectin 3 [10]. Immunologic modula-
tion is also a phenomenon encountered both in pregnancy,
and in tumor proliferationwhich allows the presence, growth,
and development of semiallogeneic cells (fetus and tumour).
40% of cells of the decidua, in a pregnant uterus, are immune
cells (NK, macrophages and dendrocytes). Uterus NK (70%
of uterus immune cells) are CD16 (−) which means that
they lack cytotoxic capacity. They also secrete galectin-1,
responsible for induction of a tolerant behaviour in dendritic
cells (DC). CD16 (−)NKcells infiltrated in tumours, like renal
cell carcinoma, have been taken as responsible for reducing
cytotoxic activity and modulating DC immune activity on
these tumours [10]. Regulatory T cells (present both in nor-
mal pregnancy and cancer) have an important role in increas-
ing tumor blood vessel density and in impaired antitumor
immunity [10]. Still very little is known about the relationship
between these events in pregnancy and in tumorogenesis.
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